**DEVELOPMENT        AGREEMENT**

**Neuro-Hitech        Pharmaceuticals, Inc.**

**Formerly:        Marco Hi-Tech JV Ltd**

**Org        Syn Laboratory, Inc.**

**OrgSyn**

**SUBJECT**

| **1.** | **COMPENSATION** |
|--------|------------------|

|   | 1.1. | In                  return for the development work specified in Attachment A, Hi-Tech                  agrees                  to pay fees in                  US Dollars as per the Summary Table of Attachment A. It                  is agreed and understood by both                  sides that this agreement covers execution of work specified in                  the scope of work (see                  Attachment A). |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **2.** | **DUTIES****OF                  ORGSYN** |
|--------|------------------------------------------|

|   | 2.1 | OrgSyn                  shall be responsible for managing the development work and performing                  all activities                  necessary to provide Hi-Tech with all the information it                  requires to file the Chemistry                  Manufacturing and Controls (CMC) Section of an NDA for the Product                  with the                  FDA. Orgsyn will address all questions and deficiencies related                  to                  its part in the CMC                  section of the NDA within a reasonable                  time. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**The        duties of ORGSYN shall include:**

|   | 2.2 | Synthetic                  process of Huperzine A shall be developed by Orgsyn as per the                  scope                  of work outlined in Attachment A                  provided. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.3 | Source                  raw materials for the product. |
|--------|-----|--------------------------------------------------------|

----

|   | 2.4 | Establish                  specifications and test methods for the raw materials. For pharmacopeal                  monographs                  materials, the USP monograph should be used, and other tests should                  be                  included as appropriate. All non-pharmacopeal substances must have                  a                  current active                  DMF within the FDA and the DMF specifications are to be used. For                  the API                  and                  related substances the assay should be validated by the                  OrgSyn. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.5 | Manage                  and supervise the production of scale up batches of the                  Product. |
|--------|-----|-----------------------------------------------------------------------------------------------------------|

|   | 2.6 | During                  the development period, prepare and submit to Hi-Tech monthly progress                  reports, based on an mutually agreed                  schedule. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.7 | Assemble                  all relevant chemistry manufacturing and controls data (except                  for those                  directly related to the submission batches that will be produced                  by                  Hi-Tech) necessary for the                  submission. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.8 | Provide                  CMC section of the pharmaceutical development report for submission                  purposes. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------|

|   | 2.9 | Provide                  in a timely manner responses to all US FDA issues, questions and                  comments                  following screening and/or review of chemistry manufacturing data                  including additional tests or development work that will be                  requested. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.10 | Validate                  all analytical methods that require validation. These methods include                  all                  assay tests for the active and its related                  substances. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.11 | OrgSyn                  will be responsible for the purity of chemicals used in the                  synthesis. |
|--------|------|-----------------------------------------------------------------------------------------------------------------|

|   | 2.12 | If                  required, OrgSyn will work with outside analytical lab to develop                  validayed analytical methods such as HPLC, OrgSyn will use the                  method and,                  in turn, determine whether our drug substance meets the purity                  criteria,                  and then OrgSyn submits the drug substance to the analytical laboratory                  for an independent confirmation of the purity and then                  releases. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **3.** | **COORDINATION** |
|--------|------------------|

| **4.** | **TERMS                  AND TERMINATION** |
|--------|--------------------------------------------|

|   | 4.1 | This                  Agreement shall continue in effect until the end of the development                  program, unless terminated earlier pursuant to this                  Section. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.2 | Either                  party shall have the right to terminate this Agreement immediately                  upon                  written notice to the other party if: (i) a petition is filed by                  or                  against the other party in bankruptcy, for the appointment of a                  receiver,                  or in reorganization under the provisions of any applicable bankruptcy                  law; or (ii) the other party makes any assignment for the benefit                  of                  creditors. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.3 | Either                  party shall have the right to terminate this Agreement immediately                  upon                  written notice to the other party if the other party is in material                  breach                  of any of the terms of this agreement and fails to remedy such                  breach                  within ninety days after written notice of such                  breach. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 4.4 | Hi-Tech                  shall have the right to terminate this Agreement upon written notice                  to                  Org-Syn                  if OrgSyn fails to achieve any Milestone as set up in Attachment                  A within                  60 days                  of                  the deadlines above or on mutually agreed upon time                  lines. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **5.** | **PROPRIETORY                  RIGHT TO DEVELOPMENT DATA** |
|--------|------------------------------------------------------------|

|   | 5.1 | Hi-Tech                  will have ownership rights in the Hi-Tech Territory to the data                  generated                  by OrgSyn. OrgSyn agrees to assist in obtaining patents for Hi-Tech                  for                  the data generated                  by OrgSyn. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **6.** | **CONFIDENTIALITY** |
|--------|---------------------|

*provided,        *
*however,        *
*provided,        further, *

| **7.** | **REPRESENTATIONS                  AND WARANTIES** |
|--------|----------------------------------------------------|

|   | 7.1 | Mutual                  Representations and Warranties of Hi-Tech and                  UNIQUE |
|--------|-----|-----------------------------------------------------------------------------------------------|

|   | (a) | Organization.   Such                  party is duly organized, validly existing and in good standing                  under the laws of the jurisdiction of incorporation or organization.                  Such                  party has the requisite legal and corporate power and authority                  to                  conduct                  its business as presently being conducted and as proposed to be                  conducted                  by it and is duly qualified to do business in those jurisdictions                  where                  its ownership of property or the conduct of its business                  requires. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Authority.   Such                  party has all requisite legal and corporate power and authority                  to enter into this Agreement and to perform the services contemplated                  hereunder (including, in the case of Hi-Tech, the manufacture of                  the Product). All corporate actions on the part of such party,                  the boards                  of director                  or managers, or similar governing body of such party (i) the                  authorization, execution, delivery and performance by such party                  of this                  Agreement,                  and (ii) the consummation of the transactions contemplated                  hereby,                  have been duly taken. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (c) | Binding                  Obligation.   This                  Agreement is a legally valid and binding obligation of                  such party, enforceable against such party in accordance with its                  terms                  (except                  in all cases as such enforceability may be limited by applicable                  bankruptcy,                  insolvency, reorganization, moratorium, or similar laws affecting                  the                  enforcement of creditors' rights generally and except that the                  availability of                  the equitable remedy of specific performance or injunctive relief                  is                  subject to                  the discretion of the court before which any proceeding may be                  brought). |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | No                  Conflicts.   None                  of the execution and delivery of this                  Agreement,                  the consummation                  of the transactions provided for herein or contemplated hereby,                  or the fulfillment by such party of the terms hereof or thereof,                  will                  (with                  or without notice or passage of time or both) (i) conflict with                  or result                  in a breach                  of any provision of the certificate or articles of incorporation                  or                  formation,                  by-laws, statutes, operating agreement or other governing documents                  of such party, (ii) result in a default, constitute a default under,                  give                  rise to any right of termination, cancellation or acceleration,                  or require                  any                  consent or approval (other than approvals that have heretofore                  been                  obtained)                  of any governmental authority or under any of the terms, conditions                  or                  provisions of any material note, bond, mortgage, indenture, loan,                  arrangement,                  license, agreement, lease or other instrument or                  obligation                  to which                  such party is a party or by which its assets may be bound, or (iii)                  violate                  any law or regulation applicable to such party or any of its                  assets. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (g) | Consents                  and Approvals.   All                  material consents, approvals, qualifications, orders                  or authorizations of, filings with, or notices to any governmental                  authority                  or any other Person required in connection                  with                  such party's execution,                  delivery or performance of (i) this Agreement, and (ii) the consummation                  of any other transaction contemplated on the part                  of                  such party                  hereby have been obtained, made or                  given. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (h) | No                  Violation of Law; Permits.   Orgsyn                  and Hi Tech in USA are not in violation of                  any law or regulation (nor is such party aware of any violation                  of any law                  or regulation                  by any other Person), which violation could reasonably be expected                  to adversely affect such party's performance of its obligations                  hereunder                  or the ability of the other party to realize the intended benefits                  to                  such                  other party under this Agreement, and, except as otherwise contemplated                  hereby, such party holds each of the licenses, permits, approvals                  or authorizations necessary with respect to its current business                  and                  operations (and its rights and obligations contemplated hereby)                  in                  compliance                  with all laws and regulations. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **8.** | **INDEMNIFICATION** |
|--------|---------------------|

| **9.** | **ARBITRATION** |
|--------|-----------------|

|   | 9.1 | All                  claims, disputes and other matters arising in connection with this                  Agreement or the performance                  thereof, including but not limited to questions as to                  whether                  a mailer is governed                  by this arbitration provision, shall be subject exclusively to                  and finally                  settled                  under                  the rules of conciliation and arbitration under the auspices of                  the                  AAA |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.2 | Reasonable                  discovery and production of evidence shall be allowed in arbitration,                  and                  the                  Parties agree to accept the decision of the Arbitrator regarding                  discovery                  and production of documents; |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 9.3 | All                    proceedings before the arbitrator or arbitrators shall be held                    in New York                    City, New York. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.4 | The                    costs and fees of the arbitration, including reasonable attorneys'                    fees,                    shall be allocated by the arbitrator or                    arbitrators. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.5 | The                    award rendered in arbitration shall be final, and judgment may                    be entered                    in accordance with applicable law and in any court having jurisdiction                    thereof. Notwithstanding the foregoing provisions, all rights                    of                    termination of this Agreement conferred upon either or both of                    the Parties                    hereto may be exercised by such Parties without first submitting                    the                    matter-tor arbitration. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **10.** | **ENTIRE                  AGREEMENT, AMENDMENTS** |
|---------|---------------------------------------------------|

| **11.** | **WAIVER** |
|---------|------------|

| **12.** | **SEVERABILITY** |
|---------|------------------|

| **13.** | **APPLICABLE                    LAW** |
|---------|---------------------------------------|

| **14.** | **RESTRICTED                  RELATIONSHIP** |
|---------|----------------------------------------------|

----

| **15.** | **CLINICAL                  STUDIES** |
|---------|---------------------------------------|

|   | 15.1. | Hi-Tech                  and                  Orgsyn                  will                  work                  jointly to monitor clinical bridge studies to show bioequivalence                  to Natural Huperzine A as required by the US FDA for the marketing                  approval                  of the Product as an NDA. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **16.** | **COUNTERPARTS** |
|---------|------------------|

| **17.** | **ENUREMENT** |
|---------|---------------|

**IN        WITNESS **
**WHEREOF**

| **Neuro                  Hi-Tech****Pharmaceuticals,                  Inc.** |   | **OrgSyn                  Laboratory, Inc.**                                                     |
|------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------|
|                                                                         |   |                                                                                             |
| **/s/                  Reu****ben                  Seltzer**                 |   | **/s/                  Mahendra****N.                  D****eshpande**                           |
| **Name:                  Reu****ben                  Seltzer**               |   | **Name:                  Mahendra****N.                  D****eshpande,                  Ph.D.** |
| **Title:                  Pre****sident**                                    |   | **Title:                  Pre****sident****&                  CEO**                          |
| **Date:**                                                                    |   | **Date:**                                                                                        |

----

**Attachment        A**

|   | **1.** | **GMP                  Synthesis of 80-100 gs of Huperzine A Using the Racemic****Synthesis                  Method** |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------|

|   | **2.** | **Pre                  GMP Synthesis and Analytical Work** |
|--------|--------|------------------------------------------------------------|

|   | **3.** | **New                  Asymmetric Synthesis** |
|--------|--------|-----------------------------------------------|

**1.   GMP        Synthesis of 80-100 gs of Huperzine A **
**Using        the Racemic **
**Synthesis        Method**

**2.   Pre-GMP        Synthesis and        Analytical Work**

**1**
**1**

----

**3.   New        Asymmetric Synthesis**

* *

----

**SUMMARY        TABLE**

|                                                                                                                                                                                     |                                    |                                                            |                                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **GOALS**                                                                                                                                                                                | **TIMELINE**                            | **DELIVERABLES**                                                | **COST**                                                                                                                                                                                                      |
|                                                                                                                                                                                     | **Start                  Date**         | **Delivery                  Date**                              |                                                                                                                                                                                                          | **$                  (US DOLLARS)** |
| **1.  ****GMP                  Synthesis****of                  80-100 gs****Of****Huperzine                  A Using****the****Racemic****Synthesis                  Method** | Date                  ofcontractsigning | 7                  months fromcontract                  signing | 80-100                  gs of GMPHuperzine                  A                                                                                                                                                 | Start                  up funds of 67,644.00Balance67,644.00**Total                  135,328.00**  |
| **2.**  **Pre-GMP****Synthesis****and****Analytical                  Work**                                                                                                    | Date                  ofcontractsigning | 6                  months fromcontract                  signing | Master                  BatchRecord,                  theanalytical                  data anda                  certificate                  ofanalysis                  for theGMP                  product. | **Component                  1**Start                  up funds of33,833.32Balance33,833.32**Total                  67,666.64.****Component                  2**Start                  up funds of21,750.00Balance21,750.00**Total                  43,500.00**  |
| **3.  New****Asymmetric****Synthesis**                                                                                                                                         | Date                  ofcontractsigning | 6                  months fromcontract                  signing | New                  synthesis ofHuperzine                  A                                                                                                                                                 | Start                  up funds of86,500.00Balance86,500.00**Total                  173,000.00**  |

----